Palisade Bio (NASDAQ:PALI) Now Covered by Brookline Capital Management

Brookline Capital Management initiated coverage on shares of Palisade Bio (NASDAQ:PALI) in a research note issued to investors on Wednesday morning,Benzinga reports. The brokerage issued a buy rating and a $38.00 target price on the stock.

Separately, Maxim Group decreased their price target on Palisade Bio from $22.50 to $8.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

Palisade Bio Price Performance

NASDAQ PALI opened at $2.44 on Wednesday. The company has a fifty day moving average of $3.26 and a two-hundred day moving average of $4.06. The company has a market capitalization of $3.24 million, a PE ratio of -0.17 and a beta of 1.36. Palisade Bio has a 1 year low of $2.18 and a 1 year high of $22.35.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($2.32) EPS for the quarter, topping the consensus estimate of ($3.35) by $1.03. On average, research analysts expect that Palisade Bio will post -13.11 earnings per share for the current year.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.